Outcomes in adult acute promyelocytic leukemia: a decade experience

Acute promyelocytic leukemia, a distinct variant of acute myeloid leukemia (AML) accounts for 10% of AML cases. The present study was designed to analyse the clinicopathological features and outcomes in adult APL. The present report is a retrospective observational study of APL patients diagnosed between 2006 and 2018. A total of 111 were analyzed. The median age at presentation was 33 years (range, 19-60). High risk, intermediate risk and low risk were seen in 43.3%, 41.4% and 15.3% patients respectively. At a median follow up of 34 months, the event free survival and overall survival was 69.3% and 74.7% respectively. APL constituted one tenth of acute myeloid leukemia patients. Majority of patients were high risk at presentation. Sanz high risk category and bcr3 variant at presentation had significant impact on outcomes in APL
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

ConclusionT2B2F is associated with a higher incidence of acute GVHD compared with T1B2F. These results suggest that a lower dose-intensity of thiotepa and busulfan in the TBF regimen may yield better results in patients with AML in CR.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aimed to demonstrate the impact of LSCs on MRD induction day (14) and Day (28) on overall survival (OS) and disease free survival (DFS) as well as compare it to MRD status. 84 De novo adult AML patients tested for LSCs panels CD38/CD123/CD34/CD45, CD90/CD133/CD45/CD33 as well as different regular MRD panels. Day 14post induction, high expression of CD123% and CD133% had an adverse impact on both OS and DFS (p=0.004 &P=
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Purpose of review This review outlines the advancements that have been made in computational analysis for clinical flow cytometry data in hematological malignancies. Recent findings In recent years, computational analysis methods have been applied to clinical flow cytometry data of hematological malignancies with promising results. Most studies combined dimension reduction (principle component analysis) or clustering methods (FlowSOM, generalized mixture models) with machine learning classifiers (support vector machines, random forest). For diagnosis and classification of hematological malignancies, many studies have ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: CANCER BIOLOGY: Edited by Pierre Hainaut and Sophie Park Source Type: research
ConclusionsIn the largest real-world study, we demonstrate an association between factors such as age, comorbidity and AML subtypes, and the use of multiagent chemotherapy. The use of multiagent chemotherapy was associated with improved OS, particularly among patients younger than 70 years, good-risk AML and those with low Charlson comorbidity score.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 2 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fouad Kerbage, Riwa Sakr, Valerie Lapierre, Kamelia Alexandrova, Tereza Coman, Severine Leroux, Nolwenn Lucas, Sylvain Pilorge, Eric Solary, Jean-henri Bourhis, Cristina Castilla-LlorenteAbstractAllogeneic hematopoietic cell transplantation (AHCT) represents the only curative therapy for many hematological malignancies. The graft versus leukemia effect, driven by donor T cells, plays a major role in its curative potential. This effect is sometimes very evident when patients with acute myeloid leukemia and myelodysplasi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We analyzed US National Cancer Data Base of patients aged 60-79 years, who were diagnosed with acute myeloid leukemia (AML) between 2004-2014 (n=25,621). The use of multiagent versus single-agent chemotherapy was associated with a greater 1-year overall survival (43% vs. 28%), particularly for patients aged 60-69 years, those with good-risk AML or Charlson comorbidity score of 0-1.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 30 January 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Shyam A. Patel, Jonathan M. GerberAbstractFew diseases have been marked by a 40-year period of stagnation with regards to therapeutic advances and Food &Drug Administration (FDA) approvals, as has been the case for acute myeloid leukemia (AML). Cytarabine and anthracyclines were introduced for the treatment of AML in the 1970s, and in the ensuing four decades, the pharmacologic pipeline has experienced a standstill. The absence of FDA approvals in AML is not a reflection of the lack of understanding of the disease...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Few diseases have been marked by a 40-year period of stagnation with regards to therapeutic advances and Food&Drug Administration (FDA) approvals, as has been the case for acute myeloid leukemia (AML). Cytarabine and anthracyclines were introduced for the treatment of AML in the 1970s, and in the ensuing four decades, the pharmacologic pipeline has experienced a standstill. The absence of FDA approvals in AML is not a reflection of the lack of understanding of the disease biology. The field has seen major advances from the standpoint of stem cell biology and clonal evolution, and the field has also seen some therapeuti...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
ConclusionT2B2F is associated with a higher incidence of acute GVHD compared to T1B2F. These results suggest that a lower dose-intensity of thiotepa and busulfan in the TBF regimen may yield better results in AML patients in complete remission.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study suggested that a lower dose-intensity of thiotepa and busulfan (5 mg/kg thiotepa and 2 days of intravenous busulfan at 6.4 mg/kg) in the thiotepa-busulfan-fludarabine regimen may yield better outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Study